In order to build a facility at Genome Valley, Hyderabad, Bharat Serums and Vaccines Limited, which serves the gynaecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, and haematology and urology segments, has developed plans to invest between Rs 100 crore and Rs 200 crore. The company plans to set up an injectable facility. “We have acquired about ten acre at the Genome Valley. We will begin the work in a few months. Typically, an injectable plant will take about two years or so,” said Sanjiv Navangul, company Managing Director and Chief Executive Officer, on the sidelines of the ongoing industry event BioAsia. “We are a specialty drugs company with focus on women’s health from early stage to post menopause,” he said. This segment is about 20 per cent of the total pharma industry and only a few players operate in it. The segment products see high market penetration, he added.

Buy Latest Research Reports